Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1701 in Relapsed/Refractory B-Cell Lymphomas
NCT07563543Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of RN1701 in B cell lymphoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Toxicity and adverse event grading up to 12 months and Cytokine Release Syndrome grading up to 12 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
RN1701
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07563543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563543.